We are pleased to announce that Mitsuo Kawase has been appointed as new Representative Director and President, as of September 1, 2018, and that Tadahiko Inukai remains as Representative Director and Chairman.

Thank you for your continued support.

The 3rd period closing account

Patent application: “Target nucleic acid detection method” which is a new method of utilizing PAS 

The 2nd PAS production machine was installed

 (Subsidized by Monozukuri subsidy)

The 2nd period closing account

STH method which is C-PAS’s genetic testing method has been patented.

TBA expanded office to 306 at T-Biz (Currently 306,307 are used)

The capital was increased to 63.5 million Yen

(119million Yen was invested by Fukushima developing industry support fund) 

The 1st period closing account

Nucleic-acid-chromate-strip “C-PAS” has been sold to a market.